<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941603</url>
  </required_header>
  <id_info>
    <org_study_id>P05675</org_study_id>
    <secondary_id>MK-8271-004</secondary_id>
    <nct_id>NCT00941603</nct_id>
  </id_info>
  <brief_title>Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Dose-Response Efficacy and Safety Study of SCH 900271 Compared to Placebo in Subjects With Primary Hypercholesterolemia (Familial and Nonfamilial) or Mixed Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of SCH 900271 compared to placebo on the
      reduction of low-density lipoprotein cholesterol (LDL-C) from baseline to 8 weeks of
      treatment in participants with primary hypercholesterolemia (familial and nonfamilial) or
      mixed hyperlipidemia. The study will also evaluate the effect of SCH 900271 on non-high
      density lipoprotein cholesterol (non-HDL-C) and various other lipids and lipoproteins. The
      safety of SCH 900271 in this participant population will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2009</start_date>
  <completion_date type="Actual">February 22, 2010</completion_date>
  <primary_completion_date type="Actual">February 22, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Direct LDL-C at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The percentage change from baseline in the participants' LDL-C was to be evaluated at study Week 8. Standard error presented below is least squares standard error.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Direct Non-HDL-C at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The percentage change from baseline in the participants' non-HDL-C was to be evaluated at study Week 8. Standard error presented below is least squares standard error.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">619</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <condition>Mixed Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>SCH 900271 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCH 900271 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCH 900271 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCH 900271 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCH 900271 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 900271 15mg</intervention_name>
    <description>oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks</description>
    <arm_group_label>SCH 900271 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 900271</intervention_name>
    <description>oral tablets; SCH 900271 10 mg taken once daily for 8 weeks</description>
    <arm_group_label>SCH 900271 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 900271</intervention_name>
    <description>oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks</description>
    <arm_group_label>SCH 900271 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 900271</intervention_name>
    <description>oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks</description>
    <arm_group_label>SCH 900271 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 900271</intervention_name>
    <description>oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks</description>
    <arm_group_label>SCH 900271 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults of either sex 18 to 75 years of age, inclusive, with a diagnosis of primary
             hypercholesterolemia (familial and nonfamilial) or mixed hyperlipidemia (increased
             LDL-C and triglycerides [TG])

          -  must be free of any clinically significant disease, other than primary
             hypercholesterolemia or mixed hyperlipidemia that would knowingly interfere with study
             evaluations

          -  must be willing to adhere to dietary recommendations, protocol requirements, and
             provide written informed consent

        Exclusion Criteria:

        The participant will be excluded from entry if ANY of the criteria listed below are met:

          -  use of any investigational drug within 30 days of study entry

          -  female of childbearing potential or lactating

          -  postmenopausal (or perimenopausal) woman who is currently experiencing hot flashes
             (e.g. within 30 days of study entry

          -  homozygous familial hypercholesterolemia

          -  congestive heart failure New York Heart Association (NYHA) Class III or IV

          -  uncontrolled hypertension on or off therapy

          -  cardiac arrhythmia requiring medication

          -  clinical atherosclerotic disease that confers high risk for coronary heart disease
             (CHD) events (e.g. clinical CHD, symptomatic carotid artery disease, peripheral
             arterial disease, abdominal aortic aneurysm)

          -  Type 1 Diabetes Mellitus

          -  Type 2 Diabetes Mellitus

          -  history of mental instability, drug/alcohol abuse or who has been treated or is being
             treated for severe psychiatric illness, which in the opinion of the investigator, may
             interfere with optimal participation in the study

          -  gastrointestinal ulcer within 3 months of study entry

          -  history of coagulopathy

          -  history of gout

          -  known active or chronic hepatic or biliary disease.

          -  known significant impairment of renal function, dysproteinemia, nephrotic syndrome, or
             other renal disease

          -  body mass index &gt;40 kg/m^2

          -  taking non-steroidal anti-inflammatory drugs (NSAIDS) (acetaminophen and
             cyclooxygenase-2 [COX-2] inhibitors are allowed)

          -  taking more than 100 mg aspirin per day

          -  being treated with corticosteroids (oral, intramuscular, or intravascular)

          -  more than 3 alcoholic beverages per day or its equivalent (one drink equals 1.5 ounces
             of 80 proof liquor or equivalent) during study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <results_first_submitted>March 14, 2016</results_first_submitted>
  <results_first_submitted_qc>March 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 12, 2016</results_first_posted>
  <disposition_first_submitted>April 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>April 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 15, 2010</disposition_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type V</mesh_term>
    <mesh_term>Lipidoses</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=P05675&amp;kw=P05675&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SCH 900271 15 mg</title>
          <description>Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>SCH 900271 10 mg</title>
          <description>Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>SCH 900271 5 mg</title>
          <description>Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="P4">
          <title>SCH 900271 2.5 mg</title>
          <description>Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="P5">
          <title>SCH 900271 1 mg</title>
          <description>Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="105"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="104"/>
                <participants group_id="P5" count="105"/>
                <participants group_id="P6" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="101"/>
                <participants group_id="P6" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SCH 900271 15 mg</title>
          <description>Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>SCH 900271 10 mg</title>
          <description>Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>SCH 900271 5 mg</title>
          <description>Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>SCH 900271 2.5 mg</title>
          <description>Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="B5">
          <title>SCH 900271 1 mg</title>
          <description>Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="104"/>
            <count group_id="B4" value="104"/>
            <count group_id="B5" value="105"/>
            <count group_id="B6" value="97"/>
            <count group_id="B7" value="619"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="9.5"/>
                    <measurement group_id="B2" value="56.0" spread="10.8"/>
                    <measurement group_id="B3" value="56.1" spread="10.3"/>
                    <measurement group_id="B4" value="56.5" spread="8.7"/>
                    <measurement group_id="B5" value="57.5" spread="9.4"/>
                    <measurement group_id="B6" value="55.2" spread="9.5"/>
                    <measurement group_id="B7" value="56.5" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="47"/>
                    <measurement group_id="B7" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Direct LDL-C at Week 8</title>
        <description>The percentage change from baseline in the participants' LDL-C was to be evaluated at study Week 8. Standard error presented below is least squares standard error.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Intent-to-treat population defined as all participants who receive randomized treatment assignment, and have a baseline and at least one post-baseline LDL-C determination.</population>
        <group_list>
          <group group_id="O1">
            <title>SCH 900271 15 mg</title>
            <description>Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCH 900271 10 mg</title>
            <description>Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>SCH 900271 5 mg</title>
            <description>Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>SCH 900271 2.5 mg</title>
            <description>Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
          <group group_id="O5">
            <title>SCH 900271 1 mg</title>
            <description>Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Direct LDL-C at Week 8</title>
          <description>The percentage change from baseline in the participants' LDL-C was to be evaluated at study Week 8. Standard error presented below is least squares standard error.</description>
          <population>Intent-to-treat population defined as all participants who receive randomized treatment assignment, and have a baseline and at least one post-baseline LDL-C determination.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.3"/>
                    <measurement group_id="O2" value="-1.5" spread="1.3"/>
                    <measurement group_id="O3" value="-4.2" spread="1.3"/>
                    <measurement group_id="O4" value="0.2" spread="1.3"/>
                    <measurement group_id="O5" value="1.2" spread="1.3"/>
                    <measurement group_id="O6" value="1.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>ANOVA</method>
            <method_desc>Least-square (LS) means and LS standard errors based on ANOVA model extracting effects due to treatment, gender, and primary diagnosis.</method_desc>
            <param_type>Difference in percent</param_type>
            <param_value>-3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <p_value_desc>LS means and LS standard errors based on ANOVA model extracting effects due to treatment, gender, and primary diagnosis.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Difference in percent</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>LS means and LS standard errors based on ANOVA model extracting effects due to treatment, gender, and primary diagnosis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
            <param_type>Difference in percent</param_type>
            <param_value>-5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>-2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>ANOVA</method>
            <method_desc>LS means and LS standard errors based on ANOVA model extracting effects due to treatment, gender, and primary diagnosis.</method_desc>
            <param_type>Difference in percent</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>ANOVA</method>
            <method_desc>LS means and LS standard errors based on ANOVA model extracting effects due to treatment, gender, and primary diagnosis.</method_desc>
            <param_type>Difference in percent</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Direct Non-HDL-C at Week 8</title>
        <description>The percentage change from baseline in the participants' non-HDL-C was to be evaluated at study Week 8. Standard error presented below is least squares standard error.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Intent-to-treat population defined as all participants who receive randomized treatment assignment and have a baseline and at least one post-baseline non-HDL-C determination.</population>
        <group_list>
          <group group_id="O1">
            <title>SCH 900271 15 mg</title>
            <description>Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCH 900271 10 mg</title>
            <description>Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>SCH 900271 5 mg</title>
            <description>Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>SCH 900271 2.5 mg</title>
            <description>Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
          <group group_id="O5">
            <title>SCH 900271 1 mg</title>
            <description>Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Direct Non-HDL-C at Week 8</title>
          <description>The percentage change from baseline in the participants' non-HDL-C was to be evaluated at study Week 8. Standard error presented below is least squares standard error.</description>
          <population>Intent-to-treat population defined as all participants who receive randomized treatment assignment and have a baseline and at least one post-baseline non-HDL-C determination.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="102"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.2"/>
                    <measurement group_id="O2" value="-2.7" spread="1.2"/>
                    <measurement group_id="O3" value="-3.5" spread="1.2"/>
                    <measurement group_id="O4" value="-0.5" spread="1.3"/>
                    <measurement group_id="O5" value="1.6" spread="1.2"/>
                    <measurement group_id="O6" value="0.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>ANOVA</method>
            <method_desc>LS means and LS standard errors based on ANOVA model extracting effects due to treatment, gender, and primary diagnosis.</method_desc>
            <param_type>Difference in percent</param_type>
            <param_value>-3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>ANOVA</method>
            <method_desc>LS means and LS standard errors based on ANOVA model extracting effects due to treatment, gender, and primary diagnosis.</method_desc>
            <param_type>Difference in percent</param_type>
            <param_value>-3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANOVA</method>
            <method_desc>LS means and LS standard errors based on ANOVA model extracting effects due to treatment, gender, and primary diagnosis.</method_desc>
            <param_type>Difference in percent</param_type>
            <param_value>-4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>ANOVA</method>
            <method_desc>LS means and LS standard errors based on ANOVA model extracting effects due to treatment, gender, and primary diagnosis.</method_desc>
            <param_type>Difference in percent</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>ANOVA</method>
            <method_desc>LS means and LS standard errors based on ANOVA model extracting effects due to treatment, gender, and primary diagnosis.</method_desc>
            <param_type>Difference in percent</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to approximately 96 days (including 30 days following last dose for serious adverse events)</time_frame>
      <desc>Non-serious adverse events: treatment-emergent adverse events are reported. One participant in the SCH 900271 15 mg group was randomized but did not receive study drug. This participant was not included in the analyses of serious and non-serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>SCH 900271 15 mg</title>
          <description>Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>SCH 900271 10 mg</title>
          <description>Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>SCH 900271 5 mg</title>
          <description>Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="E4">
          <title>SCH 900271 2.5 mg</title>
          <description>Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="E5">
          <title>SCH 900271 1 mg</title>
          <description>Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="103"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="105"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="103"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="105"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="103"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="105"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

